Fangfang Zhang1, Yinxing Huang2, Chenyu Ding3, Guoliang Huang4, Shousen Wang3. 1. Department of Endocrinology, First Hospital of Fuzhou Affiliated to Fujian Medical University Fuzhou 350009, China. 2. Department of Neurosurgery, Fuzhou General Hospital of Nanjing Command, PLA Fuzhou 350025, China. 3. Department of Neurosurgery, Fuzong Clinical Medical College of Fujian Medical University Fuzhou 350025, China. 4. Department of Endocrinology, Union Clinical Medical College, Fujian Medical University, Fujian Institute of Endocrinology Fuzhou 350001, China.
Abstract
OBJECTIVE: The prevalence of hyperprolactinemia in non-functioning pituitary macroadenomas (NFPMAs) is not well known, and hyperprolactinemia caused by a NFPMA is currently associated with diagnostic uncertainty. Thus, the aim of this study was to evaluate the prevalence of hyperprolactinemia in NFPMAs. METHODS: A meta-analysis of all existing articles in PubMed was conducted. The search string was designed as "(non-functioning pituitary tumor OR non-functioning pituitary tumor OR non-functioning pituitary macroadenomas OR non-functioning pituitary macroadenomas OR non-functioning pituitary adenomas OR non-functioning pituitary adenomas) and hyperprolactinemia". References of the articles found were also reviewed. Study selection and data extraction were performed independently by two reviewers. Data were analyzed with STATA 11.0 software (StataCorp LP, USA). The fixed effects model was used to evaluate these studies. RESULTS: The search identified 57 published studies, seven of which were accepted for the final meta-analysis. The authors found an overall estimated 40.2% prevalence of (95% CI, 36.6%-43.7%) hyperprolactinemia in NFPMAs. CONCLUSIONS: Given the high frequency of hyperprolactinemia in NFPMAs, a diagnosis of NFPMA or prolactinoma should be made more carefully.
OBJECTIVE: The prevalence of hyperprolactinemia in non-functioning pituitary macroadenomas (NFPMAs) is not well known, and hyperprolactinemia caused by a NFPMA is currently associated with diagnostic uncertainty. Thus, the aim of this study was to evaluate the prevalence of hyperprolactinemia in NFPMAs. METHODS: A meta-analysis of all existing articles in PubMed was conducted. The search string was designed as "(non-functioning pituitary tumor OR non-functioning pituitary tumor OR non-functioning pituitary macroadenomas OR non-functioning pituitary macroadenomas OR non-functioning pituitary adenomas OR non-functioning pituitary adenomas) and hyperprolactinemia". References of the articles found were also reviewed. Study selection and data extraction were performed independently by two reviewers. Data were analyzed with STATA 11.0 software (StataCorp LP, USA). The fixed effects model was used to evaluate these studies. RESULTS: The search identified 57 published studies, seven of which were accepted for the final meta-analysis. The authors found an overall estimated 40.2% prevalence of (95% CI, 36.6%-43.7%) hyperprolactinemia in NFPMAs. CONCLUSIONS: Given the high frequency of hyperprolactinemia in NFPMAs, a diagnosis of NFPMA or prolactinoma should be made more carefully.
Authors: Felipe F Casanueva; Mark E Molitch; Janet A Schlechte; Roger Abs; Vivien Bonert; Marcello D Bronstein; Thierry Brue; Paolo Cappabianca; Annamaria Colao; Rudolf Fahlbusch; Hugo Fideleff; Moshe Hadani; Paul Kelly; David Kleinberg; Edward Laws; Josef Marek; Maurice Scanlon; Luis G Sobrinho; John A H Wass; Andrea Giustina Journal: Clin Endocrinol (Oxf) Date: 2006-08 Impact factor: 3.478
Authors: Niki Karavitaki; Gaya Thanabalasingham; Helena C A Shore; Raluca Trifanescu; Olaf Ansorge; Niki Meston; Helen E Turner; John A H Wass Journal: Clin Endocrinol (Oxf) Date: 2006-10 Impact factor: 3.478
Authors: L A Behan; E P O'Sullivan; N Glynn; C Woods; R K Crowley; T K Tun; D Smith; C J Thompson; A Agha Journal: J Endocrinol Invest Date: 2013-02-04 Impact factor: 4.256
Authors: Ana Luiza Vidal Fonseca; Leila Chimelli; Mario José C Felippe Santos; Alair Augusto S M Damas dos Santos; Alice Helena Dutra Violante Journal: Arq Neuropsiquiatr Date: 2002-09 Impact factor: 1.420
Authors: K Arita; T Uozumi; T Yano; K Kurisu; T Hirohata; K Eguchi; A Tominaga; B Pant; K Iida; H Kawamoto Journal: Endocr J Date: 1996-04 Impact factor: 2.349